Xtacy Therapeutics Corp. (TSE:XTCY) has released an update.
Xtacy Therapeutics Corp. has issued a bi-weekly update confirming the continued Management Cease Trade Order (MCTO), which restricts company executives from trading due to a delay in submitting their annual financial statements for 2023. The company, which had its MCTO issued on January 30, 2024, expects to file the overdue financial documents shortly and maintains that there have been no other material changes or failures to meet regulatory guidelines since the initial default announcement.
For further insights into TSE:XTCY stock, check out TipRanks’ Stock Analysis page.
